Reprogramming human dermal fibroblast into induced pluripotent stem cells using non-integrative Sendai virus for transduction

Abstract Introduction: Induced pluripotent stem cells (iPSC) that exhibit embryonic stem cell-like properties with unlimited self-renewal and multilineage differentiation properties, are a potential cell source in regenerative medicine and cell-based therapy. The resulting cells, induced pluripotent stem cells (iPSC), exhibited embryonic stem cell-like properties with unlimited self-renewal capacity and the ability to differentiate into cell types of all three germ layers.1,2 Sharing similar features with embryonic stem cells (ESC), the therapeutic potential of iPSC in cell-based therapies, disease modelling, drug discovery and regenerative medicine is highly promising. [...]investigations on the response of immune system on the engraftment are required.11 A pilot clinical study using autologous iPSC-derived retinal pigment epithelial cell sheet in two Japanese patients with neovascular age-related macular degeneration was reported in 2017. For the first patient at one year after transplantation, the visual acuity had not improved, though the transplanted cell sheet remained intact, and for the second patient, transplantation did not proceed due to concerns on the genetic changes detected in the cell products.12,13 Thus, extensive research and guidelines on the safety issue concerning iPSC-based cell therapy, including the genetic abnormalities and disease risks, are critical for future clinical application. [...]the defined protocols for iPSC cell production and characterisation, mode of delivery, zero-footprint gene editing protocol, and basic regulation for stem cell therapeutics are to be addressed appropriately.